Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 190Lung Neoplasms 67Ovarian Neoplasms 64Breast Neoplasms 38Fallopian Tube Neoplasms 33Small Cell Lung Carcinoma 31Parkinson Disease 4, Autosomal Dominant Lewy Body 27Carcinoma, Ovarian Epithelial 24Uterine Cervical Neoplasms 22Triple Negative Breast Neoplasms 22Squamous Cell Carcinoma of Head and Neck 19Neuroblastoma 17Carcinoma 17Adenocarcinoma of Lung 17Neoplasm Metastasis 15Endometrial Neoplasms 14Neoplasms 12Head and Neck Neoplasms 11Recurrence 8Peritoneal Neoplasms 8Carcinoma, Transitional Cell 8Esophageal Neoplasms 7Central Nervous System Neoplasms 7Brenner Tumor 7Urinary Bladder Neoplasms 6Lung Diseases 6Adenocarcinoma, Bronchiolo-Alveolar 6Thoracic Neoplasms 5Testicular Neoplasms 5Respiratory Tract Neoplasms 5

Interventions

tovorafenib 1Carboplatin 1Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Noonan Syndrome 5 × Carboplatin × Clear all
NCT05566795 2026-05-14

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Day One Biopharmaceuticals, Inc.

Phase 3 Active not recruiting
418 enrolled

Noonan Syndrome 5

Data powered by HemOnc (CC BY 4.0) Colophon âš¡